CSL Net Long-Term Debt 2017-2024 | CSLLY

CSL net long-term debt for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CSL annual net long-term debt for 2024 was $0.041B, a 97.65% decline from 2023.
  • CSL annual net long-term debt for 2023 was $1.741B, a 53.91% decline from 2022.
  • CSL annual net long-term debt for 2022 was $3.777B, a 973.9% decline from 2021.

CSL Net Long-Term Debt 2017-2024 | CSLLY

  • CSL annual net long-term debt for 2024 was $0.041B, a 97.65% decline from 2023.
  • CSL annual net long-term debt for 2023 was $1.741B, a 53.91% decline from 2022.
  • CSL annual net long-term debt for 2022 was $3.777B, a 973.9% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.8B
Amgen (AMGN)$154.9B
Gilead Sciences (GILD)$140.2B
Vertex Pharmaceuticals (VRTX)$100.3B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.8B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$58.5B
Argenex SE (ARGX)$43.6B
Insmed (INSM)$28.8B
BioNTech SE (BNTX)$24B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$19.4B
Incyte (INCY)$16.5B
Genmab (GNMSF)$16.5B
Genmab (GMAB)$16B
Illumina (ILMN)$15.4B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.3B
Exelixis (EXEL)$10.1B
Moderna (MRNA)$9.4B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$9B
Bio-Techne Corp (TECH)$8.6B
Halozyme Therapeutics (HALO)$8.6B
Guardant Health (GH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B